RBC Capital Reiterates Sector Perform on PTC Therapeutics, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated a 'Sector Perform' rating on PTC Therapeutics (PTCT) and maintained a price target of $28.
March 08, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains a 'Sector Perform' rating on PTC Therapeutics with a $28 price target.
The reiteration of the 'Sector Perform' rating and maintenance of the $28 price target by RBC Capital suggests a neutral outlook on PTC Therapeutics. This indicates that the analyst sees the company performing in line with the sector, without significant short-term price movements expected. The confidence score reflects the analyst's view and the stability of the price target.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 90